Do analysts prefer TCRT or PHIO?

Phio Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 1,155.61%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TCRT or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Phio Pharmaceuticals N/A -77.34% -70.87%

Which has better earnings and valuation, ESLA or PHIO?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A

Is ESLA or PHIO more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% Phio Pharmaceuticals N/A -77.34% -70.87%

Which has better valuation and earnings, DWTX or PHIO?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A

Is DWTX or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Phio Pharmaceuticals N/A -77.34% -70.87%

Is MREO or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -81.28% -70.45% Phio Pharmaceuticals N/A -77.34% -70.87%

Phio Pharmaceuticals (PHIO) Competitors

$1.12 +0.05 (+4.21%)

As of 01:00 PM Eastern

Compare

PHIO vs. XLO, TCRT, ESLA, DWTX, and MREO

Should you buy Phio Pharmaceuticals stock or one of its competitors? MarketBeat compares Phio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phio Pharmaceuticals include Xilio Therapeutics (XLO), Alaunos Therapeutics (TCRT), Estrella Immunopharma (ESLA), Dogwood Therapeutics (DWTX), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry.

How does Phio Pharmaceuticals compare to Xilio Therapeutics?

Phio Pharmaceuticals (NASDAQ:PHIO) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Phio Pharmaceuticals' return on equity of -77.34% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,155.61%. Xilio Therapeutics has a consensus price target of $28.00, suggesting a potential upside of 227.68%. Given Phio Pharmaceuticals' higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Xilio Therapeutics had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 1.87 beat Xilio Therapeutics' score of 1.31 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phio Pharmaceuticals	Very Positive
Xilio Therapeutics	Positive

Phio Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Phio Pharmaceuticals has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Xilio Therapeutics	$53.48M	1.05	-$35.04M	-$3.55	N/A

Summary

Phio Pharmaceuticals beats Xilio Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Alaunos Therapeutics has a beta of -1.07, meaning that its share price is 207% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alaunos Therapeutics has higher revenue and earnings than Phio Pharmaceuticals. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	$3K	18,804.94	-$4.18M	-$2.13	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

Phio Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 1,155.61%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals' return on equity of -77.34% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

In the previous week, Alaunos Therapeutics had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 2 mentions for Alaunos Therapeutics and 1 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 1.87 beat Alaunos Therapeutics' score of 0.43 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
Phio Pharmaceuticals	Very Positive

Summary

Phio Pharmaceuticals beats Alaunos Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

In the previous week, Estrella Immunopharma had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 2 mentions for Estrella Immunopharma and 1 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 1.87 beat Estrella Immunopharma's score of 0.94 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Estrella Immunopharma	Positive
Phio Pharmaceuticals	Very Positive

Estrella Immunopharma's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Estrella Immunopharma presently has a consensus target price of $8.00, indicating a potential upside of 661.90%. Phio Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 1,155.61%. Given Phio Pharmaceuticals' higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Estrella Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Summary

Phio Pharmaceuticals beats Estrella Immunopharma on 6 of the 11 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Phio Pharmaceuticals' return on equity of -77.34% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Dogwood Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 1 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 1.87 beat Dogwood Therapeutics' score of 0.96 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Dogwood Therapeutics	Positive
Phio Pharmaceuticals	Very Positive

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 640.74%. Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,155.61%. Given Phio Pharmaceuticals' higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Dogwood Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Phio Pharmaceuticals beats Dogwood Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Phio Pharmaceuticals' return on equity of -77.34% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Phio Pharmaceuticals has lower revenue, but higher earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	97.37	-$41.88M	-$0.05	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 3 mentions for Mereo BioPharma Group and 1 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 1.87 beat Mereo BioPharma Group's score of 1.30 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Mereo BioPharma Group	Positive
Phio Pharmaceuticals	Very Positive

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mereo BioPharma Group has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

Mereo BioPharma Group presently has a consensus target price of $3.25, indicating a potential upside of 965.57%. Phio Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 1,155.61%. Given Phio Pharmaceuticals' higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Mereo BioPharma Group beats Phio Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Phio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHIO vs. The Competition

Export

Metric	Phio Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.96M	$2.99B	$6.50B	$12.37B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.81	18.55	23.99	24.71
Price / Sales	N/A	464.28	538.03	165.59
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.60	4.02	10.47	6.85
Net Income	-$8.70M	$75.79M	$3.56B	$337.45M
7 Day Performance	2.29%	2.31%	1.21%	2.70%
1 Month Performance	4.21%	0.02%	2.14%	4.60%
1 Year Performance	-50.88%	24.02%	26.24%	32.81%

Phio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHIO Phio Pharmaceuticals	3.7309 of 5 stars	$1.12 +4.2%	$14.00 +1,155.6%	-52.9%	$12.96M	N/A	N/A	10	Positive News
XLO Xilio Therapeutics	2.5187 of 5 stars	$7.71 +0.3%	$28.00 +263.4%	-10.4%	$50.66M	$53.48M	N/A	70	Positive News Gap Down
TCRT Alaunos Therapeutics	0.4559 of 5 stars	$2.01 +0.3%	N/A	-25.4%	$48.97M	$3K	N/A	40	Short Interest Increase Gap Up
ESLA Estrella Immunopharma	2.8308 of 5 stars	$1.14 +0.4%	$8.00 +604.8%	+10.4%	$48.84M	N/A	N/A	N/A
DWTX Dogwood Therapeutics	3.215 of 5 stars	$1.44 -1.1%	$12.00 +731.0%	-66.9%	$48.43M	N/A	N/A	5	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHIO) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. XLO, TCRT, ESLA, DWTX, and MREO

How does Phio Pharmaceuticals compare to Xilio Therapeutics?

Summary

How does Phio Pharmaceuticals compare to Alaunos Therapeutics?

Summary

How does Phio Pharmaceuticals compare to Estrella Immunopharma?

Summary

How does Phio Pharmaceuticals compare to Dogwood Therapeutics?

Summary

How does Phio Pharmaceuticals compare to Mereo BioPharma Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. XLO, TCRT, ESLA, DWTX, and MREO

How does Phio Pharmaceuticals compare to Xilio Therapeutics?

Do insiders & institutionals have more ownership in PHIO or XLO?

Is PHIO or XLO more profitable?

Do analysts recommend PHIO or XLO?

Does the media refer more to PHIO or XLO?

Which has more volatility and risk, PHIO or XLO?

Which has preferable earnings & valuation, PHIO or XLO?

Summary

How does Phio Pharmaceuticals compare to Alaunos Therapeutics?

Which has more volatility and risk, TCRT or PHIO?

Do insiders & institutionals have more ownership in TCRT or PHIO?

Which has higher earnings and valuation, TCRT or PHIO?

Do analysts prefer TCRT or PHIO?

Is TCRT or PHIO more profitable?

Does the media prefer TCRT or PHIO?

Summary

How does Phio Pharmaceuticals compare to Estrella Immunopharma?

Do institutionals and insiders believe in ESLA or PHIO?

Which has better earnings and valuation, ESLA or PHIO?

Does the media favor ESLA or PHIO?

Is ESLA or PHIO more profitable?

Do analysts rate ESLA or PHIO?

Which has more risk and volatility, ESLA or PHIO?

Summary

How does Phio Pharmaceuticals compare to Dogwood Therapeutics?

Is DWTX or PHIO more profitable?

Which has more risk & volatility, DWTX or PHIO?

Do institutionals & insiders hold more shares of DWTX or PHIO?

Which has better valuation and earnings, DWTX or PHIO?

Does the media refer more to DWTX or PHIO?

Do analysts recommend DWTX or PHIO?

Summary

How does Phio Pharmaceuticals compare to Mereo BioPharma Group?

Is MREO or PHIO more profitable?

Which has better valuation & earnings, MREO or PHIO?

Does the media refer more to MREO or PHIO?

Do institutionals and insiders have more ownership in MREO or PHIO?

Which has more risk & volatility, MREO or PHIO?

Do analysts rate MREO or PHIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools